Knee Injections for Obese Patients With Knee Arthritis

Last updated: March 6, 2026
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

4

Condition

Diabetes Prevention

Osteoarthritis

Joint Injuries

Treatment

Triamcinolone Acetonide Standard Dose

Triamcinolone Acetonide Low Dose

Clinical Study ID

NCT06782529
24-005200
  • Ages 55-85
  • All Genders

Study Summary

The purpose of this study is to assess obese patients with knee arthritis and determine the non-inferiority of a low dose steroid treatment vs. standard dose steroid treatment for two knee outcome measures: pain and function.

Eligibility Criteria

Inclusion

Inclusion Criteria:

• Patients with BMI ≥30 kg/m2 and radiograph-proven knee osteoarthritis who are interested in receiving a steroid injection for knee arthritis.

Exclusion

Exclusion Criteria:

  • BMI < 30 kg/m2

  • Uncontrolled diabetics with a hemoglobin A1c > 8%

  • No other treatment within the time frame of the study.

  • Patients that are undergoing physical therapy at the time of the study.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Triamcinolone Acetonide Standard Dose
Phase: 4
Study Start date:
January 24, 2025
Estimated Completion Date:
January 24, 2027

Connect with a study center

  • Mayo Clinic in Florida

    Jacksonville, Florida 32224
    United States

    Active - Recruiting

  • Mayo Clinic in Florida

    Jacksonville 4160021, Florida 4155751 32224
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.